Tersolisib

Tersolisib
Clinical data
Other names	LY4064809
Identifiers
	IUPAC name 1-(2-aminopyrimidin-5-yl)-3-[(1R)-1-(5,7-difluoro-3-methyl-1-benzofuran-2-yl)-2,2,2-trifluoroethyl]urea;
CAS Number	2883540-92-7;
PubChem CID	166532451;
IUPHAR/BPS	12903;
DrugBank	DB21752;
ChemSpider	128942469;
UNII	AGX9NKC8M9;
KEGG	D13290;
ChEMBL	ChEMBL5421037;
PDB ligand	ZWE (PDBe, RCSB PDB);
Chemical and physical data
Formula	C16H12F5N5O2
Molar mass	401.297 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(OC2=C1C=C(C=C2F)F)[C@H](C(F)(F)F)NC(=O)NC3=CN=C(N=C3)N;
	InChI InChI=InChI=1S/C16H12F5N5O2/c1-6-9-2-7(17)3-10(18)12(9)28-11(6)13(16(19,20)21)26-15(27)25-8-4-23-14(22)24-5-8/h2-5,13H,1H3,(H2,22,23,24)(H2,25,26,27)/t13-/m1/s1; Key:LGPNQALKGDDVBD-CYBMUJFWSA-N;

Tersolisib is an investigational new drug that is being evaluated by Eli Lilly and Company for the treatment of solid tumors. It is a PI3Kα inhibitor.